At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved |
| Targets | GLP-1R + GIPR |
| Developer | Hansoh Pharma / Regeneron |
| Modality | SC injection, once-weekly |
| Approval status | Phase 3 |
| Key efficacy | 19.3% weight loss at 48 weeks (Phase 3, Chinese cohort) |
| Indications | Obesity |
User Sentiment
Olatorepatide's patient community is currently limited to Chinese trial participants. The Regeneron partnership has raised its profile among people tracking the GLP-1 pipeline, but Western prescription data doesn't exist yet.
Example(What Phase 3 participants report)
Chinese OASIS-1 trial participants at 19.3% weight loss at 48 weeks are reporting outcomes consistent with tirzepatide-level response. Community posts from Chinese health forums describe the appetite suppression as strong and consistent with the dual-agonist class experience.
How it works
GLP-1/GIP dual agonist — same mechanistic framework as tirzepatide, single peptide activating both GLP-1R and GIPR simultaneously. The Regeneron partnership provides US development infrastructure for a drug originating from Hansoh Pharma, one of the larger Chinese pharmaceutical companies investing in the GLP-1 space.
Note(The China-to-global pipeline model)
Olatorepatide follows a pattern becoming common in GLP-1 development: a Chinese pharma (Hansoh) generates Phase 3 data domestically, validates the molecule, then partners with a Western company (Regeneron) for US/EU filing and commercialization. The Chinese Phase 3 data establishes proof of efficacy; the global Phase 3 satisfies Western regulatory requirements with a more diverse population. It's faster and cheaper than starting global Phase 3 from scratch.
Trial data
OASIS-1 (Phase 3, Chinese cohort): 19.3% weight loss at 48 weeks — competitive with tirzepatide's 19.5% at 10mg and 72 weeks. Cross-trial comparison is imprecise due to different populations and durations, but the magnitude is consistent with the GLP-1/GIP dual agonist class range. Global Phase 3 trials ongoing.
What to Expect
Based on Phase 3 Chinese cohort data and GLP-1/GIP dual mechanism:
Month 1–2 — GI side effects during escalation similar to tirzepatide class. Appetite reduction reported early.
Month 3–6 — 10–15% weight loss range expected based on trajectory.
Month 6–12 — Phase 3 data at 48 weeks showed 19.3% — the curve consistent with ongoing loss through the trial period.
Not yet available in the US or EU — global Phase 3 enrollment and readout timeline is the next milestone to watch.
Dosing and administration
Once-weekly subcutaneous injection. Full titration schedule to be confirmed in global Phase 3 [verify].
Development status
| Milestone | Status |
|---|---|
| Phase 3 Chinese cohort | Data reported — 19.3% at 48 weeks |
| Global Phase 3 | Enrolling |
| FDA filing | Pending global Phase 3 data — [verify timeline] |
Safety profile
GI profile consistent with GLP-1/GIP class based on Phase 3 Chinese cohort data. Global safety database pending completion of global trials.
Who It's For
- BMI ≥ 30 or ≥ 27 with a weight-related condition
- Type 2 diabetes patients — both indications in development
- Not currently available outside China — global Phase 3 will determine US/EU availability timeline
If you're tracking the GLP-1 pipeline for future options, olatorepatide is one to follow as Regeneron moves through global filing.
Summary(The olatorepatide picture)
19.3% weight loss at 48 weeks in Phase 3 (Chinese cohort) puts it in the tirzepatide range. Global Phase 3 is the registration path. The Regeneron partnership gives it Western commercial infrastructure — watch the global Phase 3 enrollment and readout timeline vs competitors.